178 related articles for article (PubMed ID: 38306015)
21. Preclinical Study using Malat1 Small Interfering RNA or Androgen Receptor Splicing Variant 7 Degradation Enhancer ASC-J9
Wang R; Sun Y; Li L; Niu Y; Lin W; Lin C; Antonarakis ES; Luo J; Yeh S; Chang C
Eur Urol; 2017 Nov; 72(5):835-844. PubMed ID: 28528814
[TBL] [Abstract][Full Text] [Related]
22. A Genome-Wide CRISPR Activation Screen Identifies PRRX2 as a Regulator of Enzalutamide Resistance in Prostate Cancer.
Rodríguez Y; Unno K; Truica MI; Chalmers ZR; Yoo YA; Vatapalli R; Sagar V; Yu J; Lysy B; Hussain M; Han H; Abdulkadir SA
Cancer Res; 2022 Jun; 82(11):2110-2123. PubMed ID: 35405009
[TBL] [Abstract][Full Text] [Related]
23. A Multicohort Open-label Phase II Trial of Bipolar Androgen Therapy in Men with Metastatic Castration-resistant Prostate Cancer (RESTORE): A Comparison of Post-abiraterone Versus Post-enzalutamide Cohorts.
Markowski MC; Wang H; Sullivan R; Rifkind I; Sinibaldi V; Schweizer MT; Teply BA; Ngomba N; Fu W; Carducci MA; Paller CJ; Marshall CH; Eisenberger MA; Luo J; Antonarakis ES; Denmeade SR
Eur Urol; 2021 May; 79(5):692-699. PubMed ID: 32624280
[TBL] [Abstract][Full Text] [Related]
24. Cost-Savings Analysis of AR-V7 Testing in Patients With Metastatic Castration-Resistant Prostate Cancer Eligible for Treatment With Abiraterone or Enzalutamide.
Markowski MC; Frick KD; Eshleman JR; Luo J; Antonarakis ES
Prostate; 2016 Dec; 76(16):1484-1490. PubMed ID: 27404039
[TBL] [Abstract][Full Text] [Related]
25. Targeting the androgen receptor pathway in castration-resistant prostate cancer: progresses and prospects.
Ferraldeschi R; Welti J; Luo J; Attard G; de Bono JS
Oncogene; 2015 Apr; 34(14):1745-57. PubMed ID: 24837363
[TBL] [Abstract][Full Text] [Related]
26. Analytical Validation and Clinical Qualification of a New Immunohistochemical Assay for Androgen Receptor Splice Variant-7 Protein Expression in Metastatic Castration-resistant Prostate Cancer.
Welti J; Rodrigues DN; Sharp A; Sun S; Lorente D; Riisnaes R; Figueiredo I; Zafeiriou Z; Rescigno P; de Bono JS; Plymate SR
Eur Urol; 2016 Oct; 70(4):599-608. PubMed ID: 27117751
[TBL] [Abstract][Full Text] [Related]
27. Transcriptional profiling identifies an androgen receptor activity-low, stemness program associated with enzalutamide resistance.
Alumkal JJ; Sun D; Lu E; Beer TM; Thomas GV; Latour E; Aggarwal R; Cetnar J; Ryan CJ; Tabatabaei S; Bailey S; Turina CB; Quigley DA; Guan X; Foye A; Youngren JF; Urrutia J; Huang J; Weinstein AS; Friedl V; Rettig M; Reiter RE; Spratt DE; Gleave M; Evans CP; Stuart JM; Chen Y; Feng FY; Small EJ; Witte ON; Xia Z
Proc Natl Acad Sci U S A; 2020 Jun; 117(22):12315-12323. PubMed ID: 32424106
[TBL] [Abstract][Full Text] [Related]
28. Androgen receptor gene status in plasma DNA associates with worse outcome on enzalutamide or abiraterone for castration-resistant prostate cancer: a multi-institution correlative biomarker study.
Conteduca V; Wetterskog D; Sharabiani MTA; Grande E; Fernandez-Perez MP; Jayaram A; Salvi S; Castellano D; Romanel A; Lolli C; Casadio V; Gurioli G; Amadori D; Font A; Vazquez-Estevez S; González Del Alba A; Mellado B; Fernandez-Calvo O; Méndez-Vidal MJ; Climent MA; Duran I; Gallardo E; Rodriguez A; Santander C; Sáez MI; Puente J; Gasi Tandefelt D; Wingate A; Dearnaley D; ; ; Demichelis F; De Giorgi U; Gonzalez-Billalabeitia E; Attard G
Ann Oncol; 2017 Jul; 28(7):1508-1516. PubMed ID: 28472366
[TBL] [Abstract][Full Text] [Related]
29. Downregulation of
Russo JW; Gao C; Bhasin SS; Voznesensky OS; Calagua C; Arai S; Nelson PS; Montgomery B; Mostaghel EA; Corey E; Taplin ME; Ye H; Bhasin M; Balk SP
Cancer Res; 2018 Nov; 78(22):6354-6362. PubMed ID: 30242112
[TBL] [Abstract][Full Text] [Related]
30. Plasma Androgen Receptor and Docetaxel for Metastatic Castration-resistant Prostate Cancer.
Conteduca V; Jayaram A; Romero-Laorden N; Wetterskog D; Salvi S; Gurioli G; Scarpi E; Castro E; Marin-Aguilera M; Lolli C; Schepisi G; Maugeri A; Wingate A; Farolfi A; Casadio V; Medina A; Puente J; Vidal MJM; Morales-Barrera R; Villa-Guzmán JC; Hernando S; Rodriguez-Vida A; González-Del-Alba A; Mellado B; Gonzalez-Billalabeitia E; Olmos D; Attard G; De Giorgi U
Eur Urol; 2019 Mar; 75(3):368-373. PubMed ID: 30773204
[TBL] [Abstract][Full Text] [Related]
31. Loss of Long Noncoding RNA
Ghildiyal R; Sawant M; Renganathan A; Mahajan K; Kim EH; Luo J; Dang HX; Maher CA; Feng FY; Mahajan NP
Cancer Res; 2022 Jan; 82(1):155-168. PubMed ID: 34740892
[TBL] [Abstract][Full Text] [Related]
32. Niclosamide inhibits androgen receptor variants expression and overcomes enzalutamide resistance in castration-resistant prostate cancer.
Liu C; Lou W; Zhu Y; Nadiminty N; Schwartz CT; Evans CP; Gao AC
Clin Cancer Res; 2014 Jun; 20(12):3198-3210. PubMed ID: 24740322
[TBL] [Abstract][Full Text] [Related]
33. Targeting persistent androgen receptor signaling in castration-resistant prostate cancer.
Graham L; Schweizer MT
Med Oncol; 2016 May; 33(5):44. PubMed ID: 27042852
[TBL] [Abstract][Full Text] [Related]
34. Restoration of the cellular secretory milieu overrides androgen dependence of in vivo generated castration resistant prostate cancer cells overexpressing the androgen receptor.
Patki M; Huang Y; Ratnam M
Biochem Biophys Res Commun; 2016 Jul; 476(2):69-74. PubMed ID: 27179779
[TBL] [Abstract][Full Text] [Related]
35. Androgen receptor degraders overcome common resistance mechanisms developed during prostate cancer treatment.
Kregel S; Wang C; Han X; Xiao L; Fernandez-Salas E; Bawa P; McCollum BL; Wilder-Romans K; Apel IJ; Cao X; Speers C; Wang S; Chinnaiyan AM
Neoplasia; 2020 Feb; 22(2):111-119. PubMed ID: 31931431
[TBL] [Abstract][Full Text] [Related]
36. Clinical Significance of Androgen Receptor Splice Variant-7 mRNA Detection in Circulating Tumor Cells of Men With Metastatic Castration-Resistant Prostate Cancer Treated With First- and Second-Line Abiraterone and Enzalutamide.
Antonarakis ES; Lu C; Luber B; Wang H; Chen Y; Zhu Y; Silberstein JL; Taylor MN; Maughan BL; Denmeade SR; Pienta KJ; Paller CJ; Carducci MA; Eisenberger MA; Luo J
J Clin Oncol; 2017 Jul; 35(19):2149-2156. PubMed ID: 28384066
[TBL] [Abstract][Full Text] [Related]
37. Prospective Multicenter Validation of Androgen Receptor Splice Variant 7 and Hormone Therapy Resistance in High-Risk Castration-Resistant Prostate Cancer: The PROPHECY Study.
Armstrong AJ; Halabi S; Luo J; Nanus DM; Giannakakou P; Szmulewitz RZ; Danila DC; Healy P; Anand M; Rothwell CJ; Rasmussen J; Thornburg B; Berry WR; Wilder RS; Lu C; Chen Y; Silberstein JL; Kemeny G; Galletti G; Somarelli JA; Gupta S; Gregory SG; Scher HI; Dittamore R; Tagawa ST; Antonarakis ES; George DJ
J Clin Oncol; 2019 May; 37(13):1120-1129. PubMed ID: 30865549
[TBL] [Abstract][Full Text] [Related]
38. IU1 and enzalutamide combination yields synergistic effects on castration-resistant prostate cancer.
Zhang Y; Liao Y; Luo M; Ye Y; Xu Z; Hou W; Liu R; Zhai Q; Lv S; Wei Q
Prostate; 2023 Nov; 83(15):1446-1457. PubMed ID: 37545197
[TBL] [Abstract][Full Text] [Related]
39. Newly developed preclinical models reveal broad-spectrum CDK inhibitors as potent drugs for CRPC exhibiting primary resistance to enzalutamide.
Matsuoka T; Sugiyama A; Miyawaki Y; Hidaka Y; Okuno Y; Sakai H; Tanaka H; Yoshikawa K; Fukui T; Mizuno K; Sumiyoshi T; Goto T; Inoue T; Akamatsu S; Kobayashi T; Nakamura E
Cancer Sci; 2024 Jan; 115(1):283-297. PubMed ID: 37923364
[TBL] [Abstract][Full Text] [Related]
40. Structural and molecular insights into the mechanism of resistance to enzalutamide by the clinical mutants in androgen receptor (AR) in castration-resistant prostate cancer (CRPC) patients.
Khan A; Mao Y; Tahreem S; Wei DQ; Wang Y
Int J Biol Macromol; 2022 Oct; 218():856-865. PubMed ID: 35905763
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
